Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION Pediatric-plan strategist in an RWE group proposing a post-marketing study instead of a new RCT has one working extract — complete-response-letter deficiency list — after an FAERS cluster in a demographic the trials under-enrolled. If complete-response-letter deficiency list cannot support to drop a secondary, the only defensible Pharma & Life Sciences output is hold.

DECISION Pediatric-plan strategist in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using complete-response-letter deficiency list after an FAERS cluster in a demographic the trials under-enrolled.

HYPOTHESES TO TEST 1. The population in complete-response-letter deficiency list is the one an FAERS cluster in a demographic the trials under-enrolled named, so Proceed under protocol follows for this FDA Response and Labeling file. 2. The population in complete-response-letter deficiency list is adjacent only to an FAERS cluster in a demographic the trials under-enrolled; Pause the pathway is the honest Pharma & Life Sciences call. 3. An RWE group proposing a post-marketing study instead of a new RCT already contained an FAERS cluster in a demographic the trials under-enrolled before complete-response-letter deficiency list arrived; no new FDA Response and Labeling path. 4. Provenance on complete-response-letter deficiency list after an FAERS cluster in a demographic the trials under-enrolled is broken; do not pick Proceed under protocol or Pause the pathway yet.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in complete-response-letter deficiency list after an FAERS cluster in a demographic the trials under-enrolled. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read complete-response-letter deficiency list against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move to drop a secondary for pediatric-plan strategist.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (complete-response-letter deficiency list after an FAERS cluster in a demographic the trials under-enrolled). If complete-response-letter deficiency list cannot force a Pharma & Life Sciences label under FDA Response and Labeling, stop. Do not invent missing evidence an RWE group proposing a post-marketing study instead of a new RCT does not have.